Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Takashi Seto, Masashi Kimura, Y. Kogure, Kenichi Suzuki, Toshinobu Hayashi, Mototsugu Shimokawa, Tomomi Takiguchi, Takeshi Koike, Satoru Shimizu, Makoto Nishio, Reiko Matsui, Tomohiko Harada, Kimiko Fujiwara, Naoyuki Nogami, Hirotsugu Kenmotsu, Koichi Goto, Hiroyasu Kaneda
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
Background Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods In this multicenter, prospective,
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-8 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-8 (2020)
Background Hyponatremia, a marker of disease severity and prognosis, has been associated with various clinical factors and drug use, especially diuretics. Methods This observational prospective cohort study enrolled patients hospitalized at the Unive
Autor:
Maria Paula Marques, Eduardo Barbosa Coelho, Guilherme Suarez-Kurtz, Jurandyr Moreira de Andrade, Vera Lucia Lanchote, João Paulo Bianchi Ximenez
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 20, Iss S1, Pp 1-10 (2019)
BMC Pharmacology and Toxicology, Vol 20, Iss S1, Pp 1-10 (2019)
Background Tamoxifen is considered a prodrug of its active metabolite endoxifen, which is dependent on the CYP2D6 and CYP3A enzymes. Tamoxifen pharmacokinetic variability influences endoxifen exposure and, consequently, its clinical outcome. This stu
Autor:
Alemseged Beyene Berha, Workineh Shibeshi, Anandi N. Sheth, Getnet Yimer, Addisu Admasu, Zenebe Negash
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
Background Nephrotoxicity and ototoxicity are clinically significant dose-related adverse effects associated with second-line anti-tubercular injectables drugs (aminoglycosides and capreomycin) used during intensive phase of treatment of multi-drug r
Autor:
Chenguang Zhou, Li Ren, Weijin Zhao, Xiaohong Sun, Yi Sui, Bing Xu, Pingmei Song, Chunyao Dong
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-5 (2018)
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-5 (2018)
Background Valproic acid (VPA) and warfarin are commonly prescribed for patients with epilepsy and concomitant atrial fibrillation (AF). When VPA and warfarin are prescribed together, clinically important interactions may occur. VPA may replace warfa
Autor:
Xin Yu, Qiujie Zhang, Jianbo Zhang, Fei Yu, Kuanxiao Tang, Tao Peng, Liyan Li, Nan Chen, Liwei Liu, Yun-peng Zhao
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-12 (2018)
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-12 (2018)
Background Adefovir dipivoxil (ADV)-induced renal tubular dysfunction and hypophosphatemic osteomalacia (HO) have been given great consideration in the past few years. However, no standard guidance is available due to a lack of powerful evidence from
Autor:
Sang-Hyun Kim, Jun Kwan, Tae Ho Park, Shung Chull Chae, Kiyuk Chang, Taehoon Ahn, Chi Young Shim, Kook Jin Chun, Jae Kean Ryu, Tae Soo Kang, Doo Il Kim, Myung Ho Jeong, In Ho Chae, Seung Jae Joo, Young Won Yoon, Deuk Young Nah, Hong Seog Seo, Ki Chul Sung, Seok Yeon Kim, Jin Ok Jeong, Moo Yong Rhee, Seung-Jea Tahk, Dong Gu Shin, Wan Joo Shim, Hae Young Lee, Sung Yun Lee, Dong Joo Oh, Seung Woo Park, Tae Hyun Yang
Publikováno v:
BMC Pharmacology & Toxicology
BMC PHARMACOLOGY & TOXICOLOGY(18)
BMC PHARMACOLOGY & TOXICOLOGY(18)
Background Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hyper
Publikováno v:
BMC Pharmacology & Toxicology
Background Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the activation of naïve T cells by binding the CD80 and CD86 molecules expressed on the surface of dendritic cells, indicated for the treatment of mod
Publikováno v:
BMC Pharmacology & Toxicology
Background Many antibiotics have no effect on Gram-positive and Gram-negative microbes, which necessitates the prescription of broad-spectrum antimicrobial agents that can lead to increased risk of antibiotic resistance. These pathogens constitute a
Autor:
Adeline Rollin-Sillaire, Emilie Le Rhun, Xavier Delbeuck, Florence Pasquier, Marie-Anne Mackowiak, Marianne Pollet, Marie-Pierre Noel, Thierry Facon, P. Lenfant, Xavier Leleu
Publikováno v:
BMC Pharmacology & Toxicology
Background There are many reports of cognitive dysfunction in patients receiving chemotherapy or targeted therapies. Many antineoplastic agents may be involved in the condition also known as “chemo brain” or “chemo fog”. Case presentation Two